Last Updated: June 24, 2026

List of Excipients in Branded Drug GOOD NEIGHBOR PHARMACY


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing GOOD NEIGHBOR PHARMACY

Excipient Strategy and Commercial Opportunities for GOOD NEIGHBOR PHARMACY

Last updated: March 2, 2026

What is the excipient profile for GOOD NEIGHBOR PHARMACY?

The product's excipient composition is crucial for formulation stability, bioavailability, patient safety, and regulatory compliance. Typically, excipients in solid oral dosage forms like tablets or capsules include fillers, binders, disintegrants, lubricants, and coatings.

  • Fillers: Microcrystalline cellulose, lactose monohydrate, or mannitol to provide bulk.
  • Binders: Hydroxypropyl methylcellulose (HPMC) or povidone to hold tablet ingredients together.
  • Disintegrants: Croscarmellose sodium or sodium starch glycolate to promote breakup in the GI tract.
  • Lubricants: Magnesium stearate to facilitate manufacturing.
  • Coatings: Hydroxypropyl methylcellulose or film-forming agents for stability and controlled release.

The selection depends on drug properties, release profile, manufacturing process, and patient safety.

What are key considerations for excipient strategy?

  1. Regulatory Compliance: Use of excipients with established safety profiles (generally recognized as safe, GRAS). FDA, EMA, and other authorities maintain lists of approved excipients.
  2. Formulation Stability: Compatibility of excipients with the active pharmaceutical ingredient (API). Conduct stability testing to prevent degradation.
  3. Manufacturing Compatibility: Excipients should optimize flow properties, compression behavior, and scale-up processes.
  4. Patient Safety & Tolerability: Minimize excipient-related adverse effects, such as lactose intolerance issues or hypersensitivity to specific binders.
  5. Cost Efficiency: Select excipients balancing performance with affordability for market competitiveness.
  6. Differentiation & Innovation: Use novel excipients or delivery systems (e.g., controlled-release matrices, liquisolid systems) to elevate product profile.

What commercial opportunities does excipient strategy unlock?

Differentiation through formulation

  • Improved bioavailability using specialized excipients can enable formulations with lower dose requirements or extended-release profiles.
  • Specialty excipients (e.g., mucoadhesive polymers, solubilizers) can enable niche delivery pathways, such as targeted or orphan indications.

Cost advantage

  • Economies of scale in sourcing commonly used excipients reduce manufacturing costs.
  • Simplified formulations with fewer excipients lower regulatory complexity and development timelines.

Regulatory positioning

  • Use of excipients with long regulatory histories expedites approvals.
  • Demonstrating excipient safety can open markets with strict regulations (e.g., Japan, South Korea).

Market expansion

  • Developing formulations with excipients suitable for specific populations (e.g., pediatric, geriatric, allergen-free) broadens customer base.
  • Formulation innovations can serve niche markets or off-label uses.

Partnerships and licensing

  • Patents or proprietary excipient systems can create licensing opportunities.
  • Collaborative innovations using unique excipients can enhance product value.

How to capitalize on excipient-related opportunities?

  • Conduct comprehensive excipient screening during early formulation development.
  • Engage with excipient suppliers to develop custom or optimized excipients.
  • Leverage regulatory data to fast-track approval pathways.
  • Focus on patient-centered formulations that address specific needs.
  • Monitor market trends for emerging excipient technologies and delivery systems.

What are risks involved?

  • Regulatory delays due to excipient approval challenges.
  • Compatibility issues affecting drug stability or efficacy.
  • Patient reactions to excipient components.
  • Supply chain disruptions impacting excipient availability.

Summary table: Excipient considerations and opportunities

Aspect Details Commercial Opportunity
Regulatory Approved excipients expedite approval Faster market entry, reduced costs
Formulation Compatibility with API Stable, effective products
Patient safety Tolerability and safety profile Broader patient access, niche markets
Cost Sourcing and manufacturing costs Competitive pricing
Innovation Novel excipients/delivery systems Differentiation, premium products

Key Takeaways

  • Excipient strategy requires balancing regulatory compliance, formulation stability, and patient safety.
  • Innovations in excipient formulation can enable new delivery profiles and improve bioavailability.
  • Cost-effective, approved excipients streamline development and market entry.
  • Developing partnerships with excipient suppliers and leveraging proprietary systems create licensing opportunities.
  • Careful risk management—especially supply chain and compatibility—reduces delays and product failures.

FAQs

Q1: How does excipient selection impact regulatory approval?
Excipient selection impacts approval timelines; using excipients with established safety profiles and approved status speeds up regulatory review.

Q2: Can excipient innovation secure a competitive advantage?
Yes, novel excipients or delivery systems can differentiate products by improving efficacy, stability, or patient experience.

Q3: What are common regulatory hurdles with excipients?
Getting approval for new or unlisted excipients, ensuring compatibility with APIs, and demonstrating safety can delay development.

Q4: How should excipients be selected for pediatric formulations?
Prioritize excipients with proven safety in children, such as avoiding lactose or preservatives linked to adverse reactions, and consider patient-specific factors.

Q5: What role do excipients play in extended-release formulations?
Excipient matrices or polymers control drug release over time, enabling sustained or controlled-release profiles.


References

[1] U.S. Food and Drug Administration. (2022). Excipient guidance for industry.
[2] European Medicines Agency. (2021). Guideline on excipients in medicinal products.
[3] Sharma, R., & Koul, V. (2020). Pharmaceutical Excipients: Characteristics and regulations. Journal of Excipients & Food Chemicals, 12(4), 451-459.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.